MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board

MiNK Therapeutics, Inc.

Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.
Option granted for 4,174 shares vesting over three years under 2021 Equity Plan.
Holcomb served 23 years in U.S. Army, pioneered combat casualty care; 780+ publications.
Appointment aims to advance iNKT therapies into immune-mediated disease and pulmonary disorders.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.